{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:02:41Z","timestamp":1788364961826,"version":"build-2803163510"},"reference-count":100,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Over the past few years, there has been remarkable development in the area of optic neuritis. The discovery of new antibodies has improved our understanding of the pathology of the disease. Antiaquaporin4 antibodies and antimyelin oligodendrocytes antibodies are now considered as distinct entities of optic neuritis with their specific clinical presentation, neuroimaging characteristics, treatment options, and course of the disease. Similarly, there has been a substantial change in the treatment of optic neuritis which was earlier limited to steroids and interferons. The development of new immunosuppressant drugs and monoclonal antibodies has reduced the relapses and improved the prognosis of optic neuritis as well as an associated systemic disease. This review article tends to provide an update on the approach and management of optic neuritis.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3415_20","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:07:16Z","timestamp":1630537636000},"page":"2266-2276","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":38,"title":["Approach to optic neuritis: An update"],"prefix":"10.4103","volume":"69","author":[{"given":"Swati","family":"Phuljhele","sequence":"first","affiliation":[{"name":"Neuro-ophthalmology and Strabismus Services, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Kedar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Emory University School of Medicine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Saxena","sequence":"additional","affiliation":[{"name":"Neuro-ophthalmology and Strabismus Services, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/0301-4738.77020","article-title":"Management of optic neuritis","volume":"59","author":"Menon","year":"2011","journal-title":"Indian J Ophthalmol"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1600-0404.1980.tb03042.x","article-title":"Multiple sclerosis in North-west India","volume":"62","author":"Chopra","year":"1980","journal-title":"Acta Neurol Scand"},{"key":"B3-20240828","first-page":"1","article-title":"Multiple sclerosis and related demyelinating disorders in Indian context","volume":"35","author":"Singhal","year":"1987","journal-title":"Neurol India"},{"key":"B4-20240828","first-page":"765","article-title":"Multiple sclerosis in India:AIIMS experience","volume":"44","author":"Bhatia","year":"1996","journal-title":"J Assoc Physicians India"},{"key":"B5-20240828","first-page":"421","article-title":"Spectrum of multiple sclerosis in Delhi region","volume":"30","author":"Verma","year":"1982","journal-title":"J Assoc Physicians India"},{"key":"B6-20240828","first-page":"32","article-title":"Multiple sclerosis:Indian experience","volume":"14","author":"Singhal","year":"1985","journal-title":"Ann Acad Med Singapore"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1177\/1352458514521503","article-title":"Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India","volume":"20","author":"Pandit","year":"2014","journal-title":"Mult Scler"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4103\/0972-2327.120474","article-title":"Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings:Experience from the Mangalore demyelinating disease registry","volume":"16","author":"Pandit","year":"2013","journal-title":"Ann Indian Acad Neurol"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/0301-4738.121131","article-title":"Clinical profile and short-term outcomes of optic neuritis patients in India","volume":"62","author":"Saxena","year":"2014","journal-title":"Indian J Ophthalmol"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4103\/0028-3886.103186","article-title":"Optic neuritis:Experience from a south Indian demyelinating disease registry","volume":"60","author":"Pandit","year":"2012","journal-title":"Neurol India"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/0972-2327.192389","article-title":"Serological markers associated with neuromyelitis optica spectrum disorders in South India","volume":"19","author":"Pandit","year":"2016","journal-title":"Ann Indian Acad Neurol"},{"key":"B12-20240828","first-page":"1673","article-title":"The clinical profile of optic neuritis","volume":"109","year":"1991","journal-title":"Experience of the optic neuritis treatment trial"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/archopht.1995.01100020014004","article-title":"The optic neuritis treatment trial:Three-year follow-up results","volume":"113","author":"Beck","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2007.08.004","article-title":"Visual function 15 years after optic neuritis:A final follow-up report from the Optic Neuritis Treatment Trial","volume":"115","year":"2008","journal-title":"Ophthalmology"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","article-title":"Clinically isolated syndromes suggestive of multiple sclerosis, part I:Natural history, pathogenesis, diagnosis, and prognosis","volume":"4","author":"Miller","year":"2005","journal-title":"Lancet Neurol"},{"key":"B16-20240828","first-page":"727","article-title":"Multiple sclerosis risk after optic neuritis:Final optic neuritis treatment trial follow-up","volume":"65","year":"2008","journal-title":"Arch Neurol"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis:2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica:Distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies:A decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis Optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1212\/NXI.0000000000000339","article-title":"Female hormonal exposures and neuromyelitis optica symptom onset in a multicentre study","volume":"4","author":"Bove","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jns.2015.05.034","article-title":"Epidemiological, clinical, and immunological characteristics of neuromyelitis optica:A review","volume":"355","author":"Pereira","year":"2015","journal-title":"J Neurol Sci"},{"issue":"Supp 1","key":"B26-20240828","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.4103\/0972-2327.164816","article-title":"Neuromyelitis optica spectrum disorders:An update","volume":"18","author":"Pandit","year":"2015","journal-title":"Ann Indian Acad Neurol"},{"key":"B27-20240828","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/1874364101812010247","article-title":"Clinical characteristics, treatment outcome and predictive factors in optic neuritis","volume":"12","author":"Hansapinyo","year":"2018","journal-title":"Open Ophthalmol J"},{"key":"B28-20240828","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica:A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"B29-20240828","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0976-3147.158755","article-title":"Neuromyelitis optica and neuromyelitis optica spectrum disorder:Natural history and long-term outcome, an Indian experience","volume":"6","author":"Jagtap","year":"2015","journal-title":"J Neurosci Rural Pract"},{"key":"B30-20240828","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non-organ specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"B31-20240828","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1136\/jnnp.2004.055491","article-title":"Gluten sensitivity and neuro- myelitis optica:Two case reports","volume":"76","author":"Jacob","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B32-20240828","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder:A multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"key":"B33-20240828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B34-20240828","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3389\/fimmu.2018.02753","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated and disorders:Toward a new spectrum of inflammatory demyelinating CNS disorders","volume":"9","author":"Di Pauli","year":"2018","journal-title":"Front Immunol"},{"key":"B35-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B36-20240828","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis:Clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B37-20240828","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic and responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B38-20240828","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy:Analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol"},{"key":"B39-20240828","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/WCO.0000000000000676","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy","volume":"32","author":"Kunchok","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"B40-20240828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00415-013-6957-4","article-title":"Chronic relapsing inflammatory optic neuropathy:A systematic review of 122 cases reported","volume":"261","author":"Petzold","year":"2014","journal-title":"J Neurol"},{"key":"B41-20240828","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION):A manifestation of myelin oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J Neuroinflammation"},{"key":"B42-20240828","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B43-20240828","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0961203316683265","article-title":"Neuro-ophthalmologic manifestations in systemic lupus erythematosus","volume":"26","author":"de Andrade","year":"2017","journal-title":"Lupus"},{"key":"B44-20240828","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/03009740701218832","article-title":"Retrobulbar optic neuritis revealing primary anti-phospholipid antibody syndrome","volume":"36","author":"Marie","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"B45-20240828","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.jcjo.2018.04.013","article-title":"Atypical presentation of primary Sj\u00f6gren's syndrome as optic neuritis","volume":"54","author":"Phuljhele","year":"2019","journal-title":"Can J Ophthalmol"},{"key":"B46-20240828","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4103\/0028-3886.288976","article-title":"A Study of the clinical profile, radiologic features, and therapeutic outcomes in neurosarcoidosis from two tertiary care centers in Southern India","volume":"68","author":"Goel","year":"2020","journal-title":"Neurol India"},{"key":"B47-20240828","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrneurol.2018.14","article-title":"The current role of MRI in differentiating multiple sclerosis from its imaging mimics","volume":"14","author":"Geraldes","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"B48-20240828","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler"},{"key":"B49-20240828","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch. Neurol"},{"key":"B50-20240828","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept neuromyelitis optica (NMO) and NMO spectrum disorders","volume":"84","author":"Jacob","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B51-20240828","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO:A clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"B52-20240828","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S1474-4422(10)70168-X","article-title":"Optical coherence tomography in multiple sclerosis:A systematic review and meta-analysis","volume":"9","author":"Petzold","year":"2010","journal-title":"Lancet Neurol"},{"key":"B53-20240828","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4103\/0301-4738.121071","article-title":"Evaluation of changes in retinal nerve fiber layer thickness and visual functions in cases of optic neuritis and multiple sclerosis","volume":"61","author":"Saxena","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"B54-20240828","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.ophtha.2009.05.025","article-title":"Detection of macular ganglion cell loss in glaucoma by fourier-domain optical coherence tomography","volume":"116","author":"Tan","year":"2009","journal-title":"Ophthalmology"},{"key":"B55-20240828","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/ijo.IJO_539_17","article-title":"Retinal nerve fiber layer and ganglion cell layer changes on optical coherence tomography in early multiple sclerosis and optic neuritis cases","volume":"66","author":"Pillay","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"B56-20240828","doi-asserted-by":"crossref","first-page":"134858","DOI":"10.1155\/2013\/134858","article-title":"The afferent visual pathway:Designing a structural-functional paradigm of multiple sclerosis","volume":"2013","author":"Costello","year":"2013","journal-title":"ISRN Neurol"},{"key":"B57-20240828","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1177\/1352458511418630","article-title":"Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness","volume":"17","author":"Saidha","year":"2011","journal-title":"Mult Scler"},{"key":"B58-20240828","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis:Seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult Scler"},{"key":"B59-20240828","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archopht.1993.01090060061023","article-title":"Optic neuritis treatment trial. One-year follow-up results","volume":"111","author":"Beck","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"B60-20240828","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids- A randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol"},{"key":"B61-20240828","first-page":"CD006921","article-title":"Oral versus intravenous steroids for treatment of relapses in multiple sclerosis","volume":"8","author":"Burton","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"B62-20240828","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4103\/0301-4738.33821","article-title":"Comparative evaluation of megadose methylprednisolone with dexamethasone for treatment of primary typical optic neuritis","volume":"55","author":"Menon","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"B63-20240828","first-page":"CD001430","article-title":"Corticosteroids for treating optic neuritis","volume":"2015","author":"Gal","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B64-20240828","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica:Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"B65-20240828","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.msard.2018.01.010","article-title":"Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders","volume":"20","author":"Srisupa-Olan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"B66-20240828","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B67-20240828","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica:Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"key":"B68-20240828","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1468-1331.2008.02258.x","article-title":"Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin","volume":"15","author":"Tselis","year":"2008","journal-title":"Eur J Neurol"},{"key":"B69-20240828","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","article-title":"Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis:A randomized, double-blind, placebo-controlled trial","volume":"61","author":"Achiron","year":"2004","journal-title":"Arch Neurol"},{"key":"B70-20240828","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis:Lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front Neurol"},{"key":"B71-20240828","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"B72-20240828","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/01.wnl.0000200778.65597.ae","article-title":"IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event","volume":"66","author":"Kinkel","year":"2006","journal-title":"Neurology"},{"key":"B73-20240828","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis:A randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet Lond Engl"},{"key":"B74-20240828","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon b-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"Ebers","year":"1998","journal-title":"Lancet"},{"key":"B75-20240828","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","article-title":"Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:A 3-year follow-up analysis of the BENEFIT study","volume":"370","author":"Kappos","year":"2007","journal-title":"Lancet Lond Engl"},{"key":"B76-20240828","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study):A randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet Lond Engl"},{"key":"B77-20240828","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann Neurol"},{"key":"B78-20240828","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"B79-20240828","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"B80-20240828","doi-asserted-by":"crossref","first-page":"17562","DOI":"10.1177\/1756286419878324","article-title":"Extended treatment with fingolimod for relapsing multiple sclerosis:The 14-year LONGTERMS study results","volume":"12","author":"Cohen","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B81-20240828","first-page":"2055217320907951","article-title":"The ACROSS study:Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis","volume":"6","author":"Derfuss","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B82-20240828","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND):A double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"B83-20240828","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis:Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"key":"B84-20240828","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"B85-20240828","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/ijms18050940","article-title":"Natalizumab in multiple sclerosis:Long-term management","volume":"18","author":"Clerico","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B86-20240828","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40120-018-0112-1","article-title":"European and American guidelines for multiple sclerosis treatment","volume":"7","author":"Ghezzi","year":"2018","journal-title":"Neurol Ther"},{"key":"B87-20240828","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.604","article-title":"Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis:European regulators'perspective","volume":"102","author":"Anton","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B88-20240828","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine:Tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"B89-20240828","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment:Analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch Neurol"},{"key":"B90-20240828","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil:Retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"key":"B91-20240828","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","article-title":"Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies","volume":"84","author":"Kitley","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B92-20240828","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult Scler"},{"key":"B93-20240828","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/1735-1995.200275","article-title":"Efficacy and safety of rituximab in neuromyelitis optica:Review of evidence","volume":"22","author":"Etemadifar","year":"2017","journal-title":"J Res Med Sci"},{"key":"B94-20240828","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders:A systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"B95-20240828","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"B96-20240828","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/ICU.0000000000000520","article-title":"Myelin oligodendrocyte glycoprotein-IgG-associated optic neuritis","volume":"29","author":"Chun","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"B97-20240828","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12948-015-0025-9","article-title":"Rituximab in refractory sarcoidosis:A single centre experience","volume":"13","author":"Cinetto","year":"2015","journal-title":"Clin Mol Allergy"},{"key":"B98-20240828","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23573","article-title":"A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis","volume":"72","author":"S\u00fchs","year":"2012","journal-title":"Ann Neurol"},{"key":"B99-20240828","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW):A randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"The Lancet. Neurology"},{"key":"B100-20240828","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","article-title":"Phenytoin for neuroprotection in patients with acute optic neuritis:A randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Raftopoulos","year":"2016","journal-title":"Lancet Neurol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3415_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:33:42Z","timestamp":1786736022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3415_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3415_20","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"2020-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}